FDA looks at pulling speedy approvals for three cancer drugs
pharmaphorum
APRIL 27, 2021
Briefing documents published by the FDA ahead of the meeting suggest that discussion will focus on ongoing trials that may serve as alternative confirmatory studies. A similar trial called Impassion131 of Tecentriq with regular paclitaxel flopped, and even suggested patients treated with paclitaxel alone may have fared better.
Let's personalize your content